In February 2026, Lupin resolved a key US patent dispute with Astellas Pharma by agreeing to a $90 million settlement, allowing it to continue selling its generic version of mirabegron in the US
101, 46794684.10.1073/pnas.0407576101 325 SvenssonJ.LallS.DicksonS
Sameer Murali, MD, Medical Director of Obesity Medicine at Memorial Hermann Health System in Houston, Texas, explains that patients should expect a nearly identical effectiveness and safety profile compared to the name brand. They both come in the same forms and dosages, theyre taken the same way, and they both contain the same active ingredient, liraglutide
Your medication ships in discreet, cold-chain insulated packaging to maintain medication integrity in transit
HMGB1 is a ubiquitously expressed nuclear protein engaged in the progression of nucleosome stabilization and DNA binding
doi: 10.1186/s13287-021-02490-8 53 LiX.SuC.JiangZ.YangY.ZhangY.YangM.et al